New Delhi: Indigenous company Zydus Cadila has sought approval from the Drug Controller General of India (DCGI) for the emergency use of its Kovid-19 vaccine ZyCoV-D. The company said that it has conducted clinical trials for its Kovid-19 vaccine in more than 50 centers in India so far.
Zydus Cadila has said that it is a plasmid DNA vaccine against Kovid-19. Dr Sharvil Patel, managing director of Cadila Healthcare, claims that when the vaccine is approved, it will not only help adults but also people between the ages of 12 and 18.
without injection ZyCoV-D Vaccine
The Bangalore-based pharmaceutical company says that this vaccine will be injected with Pharmajet technology without the help of injection. The use of this technique will reduce the risk of side effects after the vaccine. If approved, it will be the world’s first DNA-based vaccine for the prevention of corona and the fifth available in the country.
There will be three doses of the DNA-plasmid based ‘Xycov-D’ vaccine. It can be kept at a temperature of two to four degrees Celsius and there will be no need for cold chain. With this, its consignment can be easily transported to any part of the country. The vaccine has been supported by the National Biopharma Mission (NBM) under the Biotechnology Industry Research Assistance Council (BIRAC), an undertaking under the Department of Biotechnology.
Phase III trial completed
Phase III trial of Zydus Cadila vaccine has been completed. This trial has been done on more than 28,000 volunteers. Clinical trials show that the vaccine is safe for children. The company has given the trial data to DCGI. After getting permission for emergency use, immunization of children 12-18 years of age can start by the end of July or from the first week in August.